West Pharmaceutical Services (NYSE:WST) Stock Rating Upgraded by Wolfe Research

West Pharmaceutical Services (NYSE:WST) was upgraded by research analysts at Wolfe Research to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

WST has been the subject of a number of other research reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $315.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Morgan Stanley lifted their target price on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the company an “equal weight” rating in a research note on Friday, May 29th. Stephens reissued an “overweight” rating and set a $360.00 target price on shares of West Pharmaceutical Services in a research note on Tuesday. Barclays lifted their target price on shares of West Pharmaceutical Services from $275.00 to $310.00 and gave the company an “equal weight” rating in a research note on Monday, April 27th. Finally, Evercore reissued an “outperform” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $331.91.

West Pharmaceutical Services Trading Down 1.1%

West Pharmaceutical Services stock opened at $312.77 on Monday. The company has a 50 day moving average price of $285.07 and a 200 day moving average price of $267.94. West Pharmaceutical Services has a 52 week low of $206.19 and a 52 week high of $330.88. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The firm has a market capitalization of $22.10 billion, a price-to-earnings ratio of 41.81, a P/E/G ratio of 2.65 and a beta of 1.18.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The firm had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The company’s revenue was up 21.0% on a year-over-year basis. During the same quarter last year, the business posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Research analysts forecast that West Pharmaceutical Services will post 8.6 EPS for the current year.

West Pharmaceutical Services declared that its board has authorized a share repurchase plan on Tuesday, February 17th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire up to 5.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other news, VP Annette F. Favorite sold 2,817 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the transaction, the vice president owned 16,828 shares in the company, valued at approximately $5,135,905.60. This trade represents a 14.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer owned 1,523 shares in the company, valued at $457,920.41. This represents a 37.04% decrease in their position. The SEC filing for this sale provides additional information. 0.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of WST. Norges Bank bought a new position in shares of West Pharmaceutical Services during the 4th quarter valued at $272,041,000. Generation Investment Management LLP raised its holdings in West Pharmaceutical Services by 60.0% in the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock worth $429,733,000 after acquiring an additional 585,855 shares during the period. Artisan Partners Limited Partnership raised its holdings in West Pharmaceutical Services by 22.2% in the 3rd quarter. Artisan Partners Limited Partnership now owns 2,770,920 shares of the medical instruments supplier’s stock worth $726,895,000 after acquiring an additional 503,601 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in West Pharmaceutical Services by 67.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock worth $323,280,000 after acquiring an additional 473,547 shares during the period. Finally, Steadfast Capital Management LP bought a new position in West Pharmaceutical Services in the 3rd quarter worth $123,667,000. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.